Several groundbreaking medications are reshaping blood sugar care, with Retatrutide, Cagrillintide, Tirzepatide, and Semaglutide emerging as promising choices. Retatrutide, a twin GIP and GLP-1 site agonist, exhibits remarkable body mass decrease and improved glucose regulation. Cagrillintide, on